Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

232 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galapagos NV Announces Board Changes
CI
Gilead Sciences Announces Completion of Acquisition of CymaBay
AQ
Transcript : Gilead Sciences, Inc., Q4 2023 Earnings Call, Feb 06, 2024
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
AQ
Transcript : Gilead Sciences, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Gilead quarterly results beat Street estimates as profit up on lower taxes
RE
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
GL
Transcript : Gilead Sciences, Inc., Q2 2023 Earnings Call, Aug 03, 2023
GILEAD SCIENCES, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Transcript : Gilead Sciences, Inc., Q1 2023 Earnings Call, Apr 27, 2023
Galapagos : Annual Shareholders' Meeting Results - Form 6-K
PU
Gilead Sciences : View our 2022 Environmental Social Governance Impact Report
PU
U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
AQ
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
BU
Gilead Sciences 4Q Profit Surges on Oncology, HIV Sales
DJ
Transcript : Gilead Sciences, Inc., Q4 2022 Earnings Call, Feb 02, 2023
WHO and Gilead Sciences Extend Collaborative Agreement to Enhance Access to Treatment for Visceral Leishmaniasis [press release]
AQ
Gilead Sciences Seeks M&A
CI
Gilead Sciences Again Named to Dow Jones Sustainability World Index
AQ
Gilead Sciences, Inc. - Sunlenca (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
AQ
Transcript : Gilead Sciences, Inc., Q3 2022 Earnings Call, Oct 27, 2022
Gilead reports lower 3rd-quarter profit as COVID drug sales slow
RE
Transcript : Gilead Sciences, Inc., Q2 2022 Earnings Call, Aug 02, 2022
GILEAD SCIENCES : ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS - Form 8-K
PU
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
CI
Gilead drug modestly delays breast cancer progression in late-stage trial
RE
Gilead drug modestly delays breast cancer progression in late-stage trial
RE
Gilead Sciences, Inc. Announces Executive Changes
CI
Gilead Pharmaceutical Development, Manufacturing Executive Yang to Retire
DJ
GILEAD SCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
GILEAD SCIENCES : ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS - Form 8-K
PU
Transcript : Gilead Sciences, Inc., Q1 2022 Earnings Call, Apr 28, 2022
Gilead Sciences : View First Quarter 2022 Earnings Release
PU
Transcript : Gilead Sciences, Inc. - Special Call
Gilead Sciences : Annual Report Supplement - Corporate Information
PU
Gilead Sciences : View Q4 2021 Resource Book
PU
Takeda's Ramona Sequeira Becomes Board Chair of PhRMA
AQ
Transcript : Gilead Sciences, Inc., Q4 2021 Earnings Call, Feb 01, 2022
GILEAD SCIENCES : ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS - Form 8-K
PU
Gilead Sciences : View Q4 & Full Year 2021 Earnings Release
PU
Gilead Sciences-FDA Approves Veklury (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
AQ
Transcript : Gilead Sciences, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 11:15 AM
Gilead Sciences : View Third Quarter 2021 Resource Book
PU
Gilead trims 2021 sales forecast for non-COVID products
RE
View Third Quarter 2021 Prepared Remarks
PU
Gilead trims 2021 sales forecast for non-COVID products
RE
Transcript : Gilead Sciences, Inc., Q3 2021 Earnings Call, Oct 28, 2021
View Third Quarter 2021 Earnings Release
PU
GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS - Form 8-K
PU
Gilead Sciences : View Second Quarter 2021 Prepared Remarks
PU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Daniel O\'Day
  4. News